Señales en vivo de AVTX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 may 2024 @ 16:00):

Stats
Volumen de hoy	12 413.00
Volumen promedio	678 542
Capitalización de mercado	12.08M
EPS	$0 ( 2024-05-16 )
Próxima fecha de ganancias	( $-0.190 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.230
ATR14	$0.0750 (0.64%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Truex Samantha	Buy	0
2024-03-27	Goldman Jonathan	Buy	0
2024-03-28	Kantoff Aaron	Buy	0
2023-12-20	Persson Magnus	Buy	3 334	Stock Option (Right to Buy)
2023-12-20	Almenoff June Sherie	Buy	3 334	Stock Option (Right to Buy)

INSIDER POWER
-64.35
Last 97 transactions
Buy: 5 555 925 \| Sell: 5 291 542

Volumen Correlación

Largo: 0.08 (neutral)

Corto: -0.99 (very strong negative)

Signal:(42.873) Neutral

Avalo Therapeutics, Inc. Correlación

10 Correlaciones Más Positivas
RFAIU	0.931
BOTT	0.819

10 Correlaciones Más Negativas
OZEM	-1
EIOMX	-0.917
KMDNX	-0.917
NICHX	-0.891
CCLFX	-0.869
AMCLX	-0.81

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Avalo Therapeutics, Inc. Correlación - Moneda/Commodity

0.54
( weak )

0.41
( neutral )

0.00
( neutral )

0.48
( neutral )

0.57
( weak )

-0.59
( weak negative )

Avalo Therapeutics, Inc. Finanzas

Annual	2023
Ingresos:	$1.92M
Beneficio Bruto:	$640 000 (33.26 %)
EPS:	$-113.58

FY	2023
Ingresos:	$1.92M
Beneficio Bruto:	$640 000 (33.26 %)
EPS:	$-113.58

FY	2022
Ingresos:	$18.05M
Beneficio Bruto:	$14.62M (80.98 %)
EPS:	$-1 062.68

FY	2021
Ingresos:	$5.40M
Beneficio Bruto:	$3.91M (72.38 %)
EPS:	$-9.96

Financial Reports:

No articles found.

Avalo Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn\'s disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still\'s disease, including adult-onset still\'s disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.